Company intelligence / Profile preview

CytoAgents

Pittsburgh, Pennsylvania, United Statescytoagents.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CytoAgents has completed Phase I human clinical trials demonstrating safety of CTO1681. The drug downregulates more than two dozen CRS-inducing cytokines via EP4 receptor agonism and NF-kB pathway modulation. It aims to treat or prevent life-threatening CRS without broadly suppressing the immune system. A Phase Ib/IIa trial in patients receiving CAR T-cell therapy for lymphoma has been initiated following FDA IND approval.

Therapeutic areas: OncologyImmunologyInfectious Diseases
Modalities: Small molecules (specifically, orally bioavailable immunomodulators)
Industry: Biotech

Drug pipeline

1 asset

CTO1681

Beyond the preview

Go deeper on CytoAgents.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoAgents.

Explore the full profile